Spectral Medical (TSE:EDT)
TSX:EDT
EDT Stock Chart & Stats
C$1.42
-C$0.01(-1.75%)
At close: 4:00 PM EST
C$1.42
-C$0.01(-1.75%)
Day’s Range― - ―
52-Week RangeC$0.66 - C$1.84
Previous CloseN/A
Volume37.78K
Average Volume (3M)78.93K
Market Cap
C$415.44M
Enterprise ValueC$427.60M
Total Cash (Recent Filing)C$4.07M
Total Debt (Recent Filing)C$21.09M
Price to Earnings (P/E)―
Beta0.85
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding292,562,930
10 Day Avg. Volume98,063
30 Day Avg. Volume78,934
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)-5.93
Price to Sales (P/S)169.36
P/FCF Ratio-42.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$3.49Price Target Upside145.58% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.03
Revenue Forecast (FY)C$4.99M
Bulls Say, Bears Say
Bulls Say
Focused Critical-care Product PortfolioSpectral Medical’s PMX device and companion diagnostics target a high‑severity critical care indication (sepsis/septic shock). This focused clinical niche creates durable demand, potential for specialized reimbursement, and a clear go‑to‑market value proposition that can support steady long‑term adoption if clinical benefits persist.
Attractive Product-level Gross MarginsA ~67% TTM gross margin indicates favorable unit economics for the hemoperfusion device and related consumables. If adoption expands, high gross margins provide room to absorb fixed R&D and SG&A while improving operating leverage, supporting a pathway to profitability once scale and utilization increase.
Lean Operating FootprintA small headcount implies a low fixed cost base and operational nimbleness. This lean structure can extend cash runway versus larger peers, enable focused R&D and commercialization efforts, and reduce burn per incremental revenue—advantages that support more efficient scaling if commercial traction improves.
Bears Say
Persistent Heavy Cash BurnSustained negative operating and free cash flow (~-$10.2M TTM) signals ongoing funding needs. Over multiple quarters this erodes liquidity, forces dilution or debt financing, and restricts the company’s ability to invest in commercialization and trials—threatening long‑term execution without reliable financing.
Highly Strained Balance SheetDeep negative equity and rising debt materially weaken financial flexibility. Negative equity heightens refinancing and covenant risks and increases dilution odds if capital is raised. This structural balance‑sheet weakness limits the company’s ability to pursue longer clinical programs or scale commercial operations sustainably.
Small, Volatile Revenue And Extreme LossesVery small, inconsistent revenue combined with outsized net losses indicates the business has not yet converted clinical positioning into stable sales. Extreme negative margins reflect fixed cost burdens and poor operating leverage, undermining the company’s ability to become self‑funding without significant commercial scale or cost structure change.
Spectral Medical News
EDT FAQ
What was Spectral Medical’s price range in the past 12 months?
Spectral Medical lowest stock price was C$0.66 and its highest was C$1.84 in the past 12 months.
What is Spectral Medical’s market cap?
Spectral Medical’s market cap is C$415.44M.
When is Spectral Medical’s upcoming earnings report date?
Spectral Medical’s upcoming earnings report date is May 08, 2026 which is in 32 days.
How were Spectral Medical’s earnings last quarter?
Spectral Medical released its earnings results on Mar 26, 2026. The company reported -C$0.01 earnings per share for the quarter, the consensus estimate of -C$0.01 by C$0.
Is Spectral Medical overvalued?
According to Wall Street analysts Spectral Medical’s price is currently Undervalued.
Does Spectral Medical pay dividends?
Spectral Medical pays a Notavailable dividend of C$0.12 which represents an annual dividend yield of N/A. See more information on Spectral Medical dividends here
What is Spectral Medical’s EPS estimate?
Spectral Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Spectral Medical have?
Spectral Medical has 292,562,930 shares outstanding.
What happened to Spectral Medical’s price movement after its last earnings report?
Spectral Medical reported an EPS of -C$0.01 in its last earnings report, expectations of -C$0.01. Following the earnings report the stock price went down -2.055%.
Which hedge fund is a major shareholder of Spectral Medical?
Currently, no hedge funds are holding shares in TSE:EDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Spectral Medical
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
EDT Stock 12 Month Forecast
Average Price Target
C$3.49
▲(145.58% Upside)
Technical Analysis
Cipher Pharmaceuticals
―
BioMark Diagnostics
―
kneat.com
―
Profound Medical
―
Sona Nanotech Inc
―
Options Prices
Currently, No data available
---